Gastrointestinal stromal tumour

Executive Summary

Gastrointestinal stromal tumours (GISTs) are the most common mesenchymal neoplasms of the gastrointestinal (GI) tract, though they remain rare overall, accounting for approximately 1–2% of all primary GI malignancies. Unlike gastric or colorectal adenocarcinomas—which arise from the epithelial lining—GISTs originate from the interstitial cells of Cajal (ICCs) or their stem cell precursors. These “pacemaker cells” regulate gut motility (peristalsis) via the KIT (CD117) receptor tyrosine kinase pathway.

The discovery that the vast majority of GISTs harbour activating mutations in KIT (≈80%) or PDGFRA (≈10%) genes revolutionised oncology, establishing GIST as the paradigm for molecularly targeted cancer therapy. The tyrosine kinase inhibitor (TKI) imatinib transformed a disease with a median survival of 18–24 months (in the metastatic setting) into a chronic, manageable condition for many patients.

This article provides a detailed, patient-centred, and clinically accurate resource covering epidemiology, pathophysiology, clinical presentation, diagnostic workup, risk stratification, treatment algorithms, follow-up, and emerging therapies.

1. Epidemiology and Demographics

Key Takeaway: While GIST can occur at any age, it is predominantly a disease of older adults. Paediatric and young adult cases require specialised genetic workup for succinate dehydrogenase (SDH) deficiency.

2. Pathophysiology and Molecular Biology

The Cell of Origin: Interstitial Cells of Cajal (ICCs)

ICCs are mesenchymal-derived cells located within the muscularis propria and myenteric plexus. They express the KIT receptor (CD117). Activation of KIT by its ligand, stem cell factor (SCF), triggers downstream signalling cascades (PI3K/AKT/mTOR, RAS/RAF/MEK/ERK, JAK/STAT) driving cell proliferation, survival, and angiogenesis.

Driver Mutations: The Molecular Taxonomy

GIST is defined by mutually exclusive “driver” mutations. Identifying the specific mutation is mandatory before starting systemic therapy, as it predicts drug sensitivity.

Clinical Pearl: PDGFRA D842V mutation confers primary resistance to imatinib, sunitinib, and regorafenib. These patients should be offered avapritinib** (first-line) or clinical trials immediately.

3. Anatomical Distribution

GISTs can arise anywhere along the GI tract, but distribution is non-uniform.

4. How Does It Look? (Gross and Microscopic Pathology)

Understanding the morphology is critical for diagnosis and risk stratification. This section details the macroscopic appearance seen by the surgeon/radiologist and the microscopic features seen by the pathologist.

Gross (Macroscopic) Appearance

• Encapsulation: Typically well-circumscribed, often surrounded by a pseudocapsule of compressed normal tissue/tumour fibroblasts. True invasion through the capsule correlates with higher risk.
• Growth Pattern: Exophytic (extraluminal) growth is classic (50–60%), protruding outward from the bowel wall. Endoluminal (intraluminal) growth occurs in ~20–25%, often causing obstruction or ulceration. Mixed patterns are common.
• Cut Surface:
• Solid areas: Firm, whorled, grey-white to tan (resembling leiomyoma).
• Degenerative changes: Cystic degeneration, haemorrhage, necrosis, and myxoid change are frequent, especially in larger tumours (>5 cm). This gives a “variegated” appearance.
• Mucosal ulceration: If the tumour breaches the mucosa, the overlying mucosa may be intact, thinned, or ulcerated (risk of GI bleeding).
• Consistency: Firm, rubbery, or fleshy depending on cellularity and necrosis.
• Rupture: Tumour rupture (spontaneous or iatrogenic during surgery) is an adverse prognostic factor (upstages to high risk in some systems) and mandates adjuvant therapy consideration.

Microscopic (Histological) Appearance

Diagnosis requires morphology + Immunohistochemistry (IHC) + Molecular confirmation.

A. Morphological Subtypes

B. Mitotic Count (The Critical Prognostic Metric)

• Method: Count mitoses per 5 mm² (equivalent to 50 high-power fields [HPF] on modern 40x objective with 0.237 mm² field diameter).
• Threshold: ≤5 per 5 mm² (Low) vs >5 per 5 mm² (High).
• Note: Atypical mitoses are rare but signify high grade.

C. Immunohistochemistry (IHC) Panel

Diagnostic Algorithm: 1. Spindle/epithelioid mesenchymal tumour in GI tract → KIT (CD117) & DOG1. 2. Double Positive → GIST (Proceed to KIT/PDGFRA mutation testing). 3. KIT Negative / DOG1 Positive → GIST likely (PDGFRA mutant or SDH-deficient) → Molecular Testing + SDHB IHC. 4. Double Negative → Not typical GIST. Consider: Leiomyosarcoma, Schwannoma, Solitary Fibrous Tumour, Desmoid, Melanoma, Sarcomatoid Carcinoma. *Rare “Quadruple Negative” GISTs exist (require NGS).

5. Clinical Presentation: Symptoms

GISTs are often asymptomatic in early stages. Symptoms correlate with tumour size, location, growth pattern (exophytic vs. endoluminal), and complications (bleeding, rupture).

Local GI Symptoms (Mechanical & Mucosal)

• Gastrointestinal Bleeding (Most Common Presentation: 25–50%):
• Overt: Haematemesis (vomiting blood), Melena (black tarry stools), Haematochezia (bright red blood per rectum – usually distal/small bowel).
• Occult: Iron deficiency anaemia (fatigue, dyspnoea, pallor) from chronic slow blood loss via ulcerated mucosa.
• Abdominal Pain/Discomfort (20–40%): Vague, dull, post-prandial fullness, or early satiety (large gastric tumours compressing stomach volume).
• Palpable Abdominal Mass (10–20%): Often discovered by patient or clinician; usually mobile unless fixed to adjacent structures (sign of locally advanced disease).
• Obstruction (5–15%): Nausea, vomiting, constipation, abdominal distension. More common with endoluminal growth in small bowel/colon. Gastric outlet obstruction occurs with large antral/pyloric tumours.
• Dysphagia / Odynophagia: Specific to oesophageal GISTs (rare).

Acute Complications (Surgical Emergencies)

• Tumour Rupture (Spontaneous or Iatrogenic): Presents as acute abdomen (severe pain, peritoneal signs, hypotension/shock from haemoperitoneum). Incidence ~5–10% at diagnosis. Major adverse prognostic factor.
• Intussusception: Tumour acts as a lead point (typically small bowel). Intermittent colicky pain, vomiting.
• Fistulisation: Rare; entero-enteric, entero-cutaneous, or entero-vesical fistulas.

Systemic / Paraneoplastic Symptoms

• Constitutional: Weight loss, anorexia, cachexia (advanced/metastatic disease).
• Hypoglycaemia (Doege-Potter Syndrome): Extremely rare; secretion of IGF-II by tumour.
• Carcinoid Syndrome: Not a feature of GIST (neuroendocrine differentiation is absent).

Asymptomatic / Incidental Detection (Increasingly Common: 20–30%)

• Found on CT/MRI/PET-CT for unrelated reasons (renal colic, trauma, screening colonoscopy, cardiac workup).
• Found during laparoscopy/cholecystectomy or other abdominal surgery.
• Endoscopic incidentaloma: Submucosal lesion (SML) noted on routine gastroscopy/colonoscopy.

Symptom Variation by Location

6. Diagnostic Workup: From Suspicion to Staging

Initial Imaging: Contrast-Enhanced CT (Triple-Phase Preferred)

• Modality of Choice: Multidetector CT (MDCT) of Chest/Abdomen/Pelvis with IV contrast. Oral contrast (water/negative) preferred for gastric/small bowel distension.
• Typical CT Appearance:
• Hypervascular mass (early arterial enhancement) → Key feature.
• Heterogeneous enhancement (necrosis, cystic change, haemorrhage) in large tumours.
• Exophytic growth with “bridging vessels” (engorged feeding vessels).
• Ulceration = mucosal discontinuity + contrast extravasation.
• Metastases: Liver (hypervascular), Peritoneum (omental caking, nodules), Rarely Lung/Bone.

Endoscopy (EGD / Colonoscopy)

• Role: Visualise mucosal surface, biopsy submucosal lesions, assess resectability.
• Appearance: Submucosal lesion (SML) with normal or ulcerated mucosa. “Pillow sign” (indenting lumen).
• Biopsy Technique: Endoscopic Ultrasound (EUS)-guided Fine Needle Aspiration (FNA) / Core Biopsy is standard for SMLs >2 cm or symptomatic. Superficial forceps biopsies often miss the tumour.
• Risk: Biopsy tract seeding is theoretical but rare; avoid if primary resection planned without neoadjuvant therapy (controversial, but many surgeons prefer no pre-op biopsy for resectable gastric GIST <5cm if imaging classic).

Endoscopic Ultrasound (EUS)

• Best for: Local staging (T-stage), assessing layer of origin (Muscularis Propria = GIST), relation to adjacent organs, lymph nodes (rare in GIST), guiding biopsy.
• EUS Features: Hypoechoic, homogeneous (solid) or heterogeneous (cystic/necrotic), well-defined margins.

PET-CT (FDG-Avid)

• Indications: Baseline metabolic activity (SUVmax) for response assessment to TKI; detecting occult metastases; evaluating equivocal CT lesions.
• Note: GISTs are highly FDG-avid. A drop in SUV >10–20% at 1–3 months predicts response (Choi criteria / PERCIST).

MRI

• Primary Role: Rectal GIST (local staging: mesorectal fascia involvement, sphincter complex).
• Secondary: Liver metastases characterisation (problem-solving for CT-indeterminate lesions); Pregnancy/Contrast allergy.

Pathology & Molecular Testing (Mandatory)

1. IHC: KIT (CD117), DOG1 (Diagnostic confirmation).
2. Mitotic Count: Per 5 mm² (Standardised).
3. Risk Stratification: (See Section 7).
4. Molecular Genotyping (NGS Panel): KIT (Exons 9, 11, 13, 17), PDGFRA (Exons 12, 14, 18), SDH genes, BRAF, NF1, RAS.

• Turnaround: 1–3 weeks. Do not delay adjuvant imatinib for results if high risk, but genotype guides dose (Exon 9 → 800mg) and duration.

7. Risk Stratification: Predicting Behaviour

No GIST is truly “benign.” All have metastatic potential. Risk stratification guides adjuvant therapy and surveillance intensity.

Modified NIH (Fletcher) Consensus Criteria (Most Widely Used)

Based on Tumour Size (cm) and Mitotic Count (per 5 mm²). Site (Gastric vs. Non-Gastric) modifies risk.

AFIP (Miettinen) Criteria / Nomograms

More granular; incorporate tumour site (Gastric vs. Duodenum/Jejenum/Ileum vs. Rectum) as continuous variables. Online nomograms (e.g., Memorial Sloan Kettering, AFIP) provide individualised recurrence-free survival (RFS) probabilities.

TNM Staging (AJCC 8th Edition / UICC)

• T: Size (T1 ≤2cm, T2 >2–5cm, T3 >5–10cm, T4 >10cm).
• N: N0 (Regional nodes rarely involved; N1 = nodal mets = Stage IV).
• M: M0 / M1 (Distant mets: Liver, Peritoneum, Lung, Bone).
• Mitotic Rate: Low (≤5/5mm²) vs High (>5/5mm²).
• Site: Gastric vs. Non-Gastric.
• Stage Grouping: I, II, IIIA, IIIB, IV.

Clinical Application: Very Low / Low Risk: Surveillance only (No adjuvant imatinib). Intermediate Risk: Discuss adjuvant imatinib (3 years considered, shared decision making). High Risk / Rupture: Adjuvant Imatinib 3 years minimum (Standard of care). Consider 5 years for highest risk (Rupture, >10cm, High Mitotic). Stage IV (Metastatic): Systemic therapy (Neoadjuvant/Downsizing or Palliative).

8. Treatment Modalities

Surgery: The Curative Intent for Localised Disease

Principles

• R0 Resection (Negative Margins): Goal. Microscopic margin (R1) increases recurrence risk.
• En Bloc Resection: Tumour + pseudocapsule + adjacent involved organs. No lymphadenectomy (nodes rarely involved).
• Avoid Tumour Rupture: “No-touch” technique. Rupture = R2 (macroscopic residual) / Upstaging.
• Minimally Invasive (Laparoscopic/Robotic): Standard for gastric GIST <5–8 cm (expert centres). Safe for selected larger tumours. Contraindicated if rupture likely.

Organ-Specific Considerations

Systemic Therapy: Tyrosine Kinase Inhibitors (TKIs)

Line 1: Imatinib (Standard Dose 400 mg daily)

• Indications: Unresectable/Metastatic (1st line); Adjuvant (High risk, 3–5 years); Neoadjuvant (Downsizing for organ preservation).
• Dosing Nuance: KIT Exon 9 mutation → 800 mg daily (400 mg BID) improves PFS/OS.
• Response Assessment: CT at 2–3 months (Choi Criteria: Size + Density/Enhancement). RECIST 1.1 underestimates response (necrosis/cystic change without size reduction).
• Duration: Continuous until progression/intolerance. Stopping leads to rapid progression (weeks-months).
• Adjuvant Duration:
• Standard: 3 years (SSGXVIII/AIO trial: 3yrs > 1yr for High Risk).
• High Risk (Rupture, >10cm, High Mitotic): 5 years (PERSIST-5, EORTC 62024 show benefit for 5yrs vs 3yrs in highest risk).

Line 2: Sunitinib (Standard Dose 50 mg daily, 4 weeks on / 2 weeks off)

• Indication: Imatinib failure (resistance/intolerance).
• Mechanism: Multi-targeted (KIT, PDGFR, VEGFR, FLT3). Anti-angiogenic.
• Efficacy: Median PFS ~5–6 months; OS benefit proven.
• Key Toxicity: Hypertension, Hand-Foot Syndrome (HFS), Fatigue, Hypothyroidism, Cytopenias. Cardiac monitoring (LVEF) required.

Line 3: Regorafenib (Standard Dose 160 mg daily, 3 weeks on / 1 week off)

• Indication: Progression on Imatinib + Sunitinib.
• Mechanism: Broad multi-kinase (KIT, VEGFR, TIE2, FGFR, BRAF, RET).
• Efficacy: Median PFS ~4.8 months (GRID trial).
• Key Toxicity: HFS (Very common), Hypertension, Fatigue, Diarrhoea, Hepatotoxicity (Monitor LFTs q2wks initially).

Line 4: Avapritinib (Standard Dose 300 mg daily continuous)

• Indication: PDGFRA Exon 18 (D842V) mutation (1st Line approved); 4th Line (post-imatinib, sunitinib, regorafenib) for KIT mutant GIST (broad approval).
• Mechanism: Potent inhibitor of PDGFRA D842V and KIT activation loop mutants (Exon 17).
• Key Toxicity: Cognitive effects (confusion, memory impairment, hallucinations), Bleeding, Oedema, Nausea. Dose reductions common. Avoid strong CYP3A4 inducers/inhibitors.

Line 4/5: Ripretinib (Standard Dose 150 mg daily, 3 weeks on / 1 week off)

• Indication: 4th Line (INVICTUS trial: post 3 prior TKIs).
• Mechanism: “Switch-control” inhibitor; broad KIT/PDGFRA coverage (including Exon 17), spares VEGFR → less hypertension/HFS.
• Key Toxicity: Alopecia (near universal), Fatigue, Nausea, Myalgia, Palmar-Plantar Erythrodysaesthesia (PPES), Cutaneous Squamous Cell Carcinoma (cuSCC) risk (Skin surveillance mandated).

Emerging / Later Lines

• Sorafenib, Pazopanib, Cabozantinib, Nilotinib, Dasatinib, Ponatinib: Used off-trial/off-label based on molecular profile (e.g., KIT Exon 17, BRAF V600E).
• Clinical Trials: Always preferred over standard 4th/5th line options. Novel agents: Bezuclastinib (CGT9486), THE-630, Elzovantinib, Immunotherapy combinations.

Management of Specific Resistance Mutations (Acquired Resistance)

On progression on Imatinib, liquid biopsy (ctDNA) or re-biopsy can identify secondary KIT mutations.

• Secondary Mutations in ATP-binding pocket (Exon 13/14): Often sensitive to Sunitinib.
• Secondary Mutations in Activation Loop (Exon 17/18): Resistant to Sunitinib/Regorafenib; Sensitive to Avapritinib / Ripretinib.
• Clonal heterogeneity: Multiple subclones common; broad inhibitors (Ripretinib) or combinations needed.

Radiation Therapy

• Role: Very limited (GIST relatively radio-resistant).
• Indications: Palliation of painful bone metastases, brain metastases (rare), unresectable local recurrence causing obstruction/bleeding not amenable to stenting/embolisation.

Interventional Radiology

• Transarterial Embolisation (TAE) / Chemoembolisation (TACE) / Radioembolisation (TARE/Y-90): For liver-dominant oligometastatic progression on TKI (“liver-only progression”) while systemic disease controlled. Can bridge to continued TKI.

9. Adverse Event Management (Supportive Care)

Proactive management maintains dose intensity and quality of life.

10. Follow-Up and Survivorship

Surveillance After Curative Resection (Adjuvant or No Adjuvant)

Goal: Detect recurrence (local/peritoneal/liver) early for potential resection/ablation + systemic therapy.

Surveillance on TKI Therapy (Metastatic/Unresectable)

• Imaging: CT Chest/Abd/Pelvis every 2–3 months (first year), then every 3–4 months.
• PET-CT: Baseline, then at 1–3 months (early response), then as needed for equivocal CT.
• Labs: CBC, CMP, Lipids, TSH (Sunitinib), q 2–4 weeks (Cycle 1), then q 4–8 weeks.
• Drug Interactions: CYP3A4 Metabolism (All TKIs).
• Strong Inhibitors (Ketoconazole, Clarithromycin, Grapefruit): ↑ TKI levels → Toxicity. Avoid or dose reduce.
• Strong Inducers (Rifampin, Phenytoin, St. John’s Wort): ↓ TKI levels → Treatment failure. Avoid.

Survivorship Issues

• GI Function: Post-gastrectomy syndrome (dumping, reflux, malabsorption B12/Iron/Calcium), Short Bowel Syndrome (multiple small bowel resections).
• Endocrine: Hypothyroidism (Sunitinib), Bone health (Vit D, DEXA scan).
• Fertility / Pregnancy: Teratogenic (Category D). Effective contraception mandatory during treatment + 2–6 weeks after (varies by drug). Imatinib: Sperm banking recommended for men (potential DNA damage); Women: stop imatinib if pregnancy planned (limited data, but teratogenic signals). Multidisciplinary counselling essential.
• Psychosocial: Fear of recurrence, financial toxicity (oral TKI costs), chronic disease burden. Referral to psycho-oncology, social work, patient advocacy groups (Life Raft Group, GIST Support International).

11. Special Populations & Clinical Scenarios

Paediatric / Young Adult GIST (<18–30 years)

• Biology: >85% Wild-Type (KIT/PDGFRA negative). Majority SDH-deficient (loss of SDHB IHC).
• Syndromes:
• Carney Triad: GIST (gastric, multifocal) + Pulmonary Chondroma + Paraganglioma (Female predominance, sporadic/epigenetic SDHC hypermethylation).
• Carney-Stratakis Dyad: GIST + Paraganglioma (Autosomal Dominant, SDHB/C/D germline mutation).
• Behaviour: Often indolent, multifocal, lymph node mets common (unlike adult GIST).
• Management: Surgery for symptomatic/large lesions. Avoid radical gastrectomy if possible. Imatinib generally ineffective (low response rates). Observation often preferred. Clinical trials (TKIs targeting SDH pathway, HIF2α inhibitors like Belzutifan) prioritised.

Neurofibromatosis Type 1 (NF1) Associated GIST

• Mechanism: NF1 loss → RAS activation (downstream of KIT). KIT/PDGFRA wild-type.
• Location: Multiple, small intestinal (duodenum/jejunum).
• Behaviour: Indolent. Multiple simultaneous primaries.
• TKI Response: Poor to Imatinib. MEK inhibitors (Selumetinib, Trametinib) show activity.

GIST in Pregnancy

• Rare. Management individualised.
• Asymptomatic/Low Risk: Defer surgery/TKI until postpartum.
• Symptomatic/High Risk: Surgery (2nd trimester safest). TKI contraindicated (Teratogenic). Multidisciplinary team (MFM, Surgical Onc, Med Onc).

Perioperative Management (Elective Surgery on TKI)

• Imatinib: Hold 24–48 hours pre-op (short half-life ~18h). Restart 24–48h post-op once haemostasis secure & oral intake resumed.
• Sunitinib/Regorafenib/Ripretinib: Hold 5–7 days pre-op (longer half-lives, anti-angiogenic → wound healing risk). Restart 7–14 days post-op (wound healed).
• Avapritinib: Hold 5–7 days pre-op (CNS effects, bleeding risk). Restart 7–14 days post-op.

12. Emerging Therapies and Future Directions

1. Next-Gen KIT Inhibitors (Targeting Resistance):

• Bezuclastinib (CGT9486): Potent against KIT Exon 17/18 + Exon 11. Phase 2/3 ongoing.
• THE-630: Designed for broad KIT mutant coverage + CNS penetration.
• Elzovantinib (TPX-0046): Targets KIT/PDGFRA + MET/CSF1R.

1. Combination Strategies:

• Imatinib + HDAC Inhibitors (Panobinostat, Quisinostat): Overcome epigenetic resistance.
• TKI + Immunotherapy (PD-1/PD-L1): Limited success monotherapy; combinations (e.g., Nivolumab + Ipilimumab + TKI) in trials.
• TKI + mTOR/PI3K/AKT inhibitors: Vertical pathway blockade.

1. Targeting SDH-Deficient GIST:

• HIF-2α Inhibitors (Belzutifan): Stabilised HIF2α drives tumorigenesis in SDH loss. Early trials promising.
• Tempol / Succinate analogues: Metabolic targeting.

1. Neoadjuvant/Adjuvant Optimisation:

• Trials testing Avapritinib/Ripretinib in adjuvant setting for specific mutations.
• ctDNA (Liquid Biopsy) for Minimal Residual Disease (MRD) detection to guide adjuvant duration.

1. Drug Holiday / Intermittent Dosing: Studies exploring controlled breaks to manage toxicity/resistance (controversial, only in trials).

13. Patient Resources and Support Organisations

• The Life Raft Group (LRG): US-based, global reach. Patient registry, research funding, mutational testing assistance, annual conference. www.liferaftgroup.org
• GIST Support International (GSI): Global online community, mailing list, expert Q&A sessions. www.gistsupport.org
• NORD (National Organization for Rare Disorders): General rare disease advocacy. www.rarediseases.org
• Sarcoma Foundation of America (SFA): Broader sarcoma support, clinical trial finder. www.curesarcoma.org
• ESMO / NCCN / NICE Patient Guides: Plain language summaries of clinical guidelines.

14. Glossary of Key Terms

• Adjuvant Therapy: Treatment given after primary surgery to reduce recurrence risk.
• Neoadjuvant Therapy: Treatment given before surgery to shrink tumour.
• R0 / R1 / R2 Resection: R0 = Microscopically negative margins; R1 = Microscopically positive margins; R2 = Macroscopic residual tumour (unresectable/rupture).
• TKI (Tyrosine Kinase Inhibitor): Oral targeted drug blocking kinase signalling.
• Driver Mutation: Genetic alteration initiating/maintaining cancer growth.
• Primary Resistance: No response to drug from start (e.g., PDGFRA D842V to Imatinib).
• Secondary (Acquired) Resistance: Initial response followed by progression due to new mutations.
• Choi Criteria: Response criteria using tumour density (Hounsfield units) + size (superior to RECIST for GIST).
• MRD (Minimal Residual Disease): Microscopic disease detectable by ctDNA but not imaging.
• cuSCC: Cutaneous Squamous Cell Carcinoma (skin cancer risk with Ripretinib).

References

1. Antonescu, C.R. (2020) ‘Gastrointestinal stromal tumours (GIST): the paradigm of targeted therapy in solid tumours’, Journal of Pathology, 250(5), pp. 602–613. doi: 10.1002/path.5398.
2. Blay, J.-Y. et al. (2021) ‘Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 32(12), pp. 1509–1526. doi: 10.1016/j.annonc.2021.08.2136.
3. Casali, P.G. et al. (2022) ‘Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Update)’, Annals of Oncology, 33(10), pp. 950–968. doi: 10.1016/j.annonc.2022.06.012.
4. Demetri, G.D. et al. (2022) ‘NCCN Guidelines Insights: Gastrointestinal Stromal Tumors, Version 2.2022’, Journal of the National Comprehensive Cancer Network, 20(7), pp. 715–725. doi: 10.6004/jnccn.2022.0039.
5. Fletcher, C.D.M. et al. (2002) ‘Diagnosis of gastrointestinal stromal tumors: A consensus approach’, International Journal of Surgical Pathology, 10(2), pp. 81–89. doi: 10.1177/106689690201000201. (Original NIH Consensus).
6. Joensuu, H. et al. (2012) ‘Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts’, The Lancet Oncology, 13(3), pp. 265–274. doi: 10.1016/S1470-2045(11)70299-6. (Modified NIH Criteria).
7. Joensuu, H. et al. (2016) ‘Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial’, Journal of Clinical Oncology, 34(3), pp. 244–250. doi: 10.1200/JCO.2015.63.0095. (SSGXVIII/AIO – 3 years vs 1 year).
8. Kang, Y.K. et al. (2021) ‘Avapritinib in patients with PDGFRA exon 18 mutant GIST (NAVIGATOR trial): a multicentre, open-label, single-arm, phase 1 trial’, The Lancet Oncology, 22(3), pp. 359–369. doi: 10.1016/S1470-2045(20)30714-9.
9. Martin Broto, J. et al. (2021) ‘Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial’, The Lancet Oncology, 22(7), pp. 949–958. doi: 10.1016/S1470-2045(21)00161-2.
10. Miettinen, M. and Lasota, J. (2006) ‘Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis’, Archives of Pathology & Laboratory Medicine, 130(10), pp. 1466–1478. doi: 10.5858/2006-130-1466-GSTRRO.
11. National Comprehensive Cancer Network (NCCN) (2024) NCCN Clinical Practice Guidelines in Oncology: Gastrointestinal Stromal Tumors (GIST). Version 1.2024. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed: 15 October 2023).
12. Reichardt, P. et al. (2023) ‘Adjuvant imatinib for 5 years versus 3 years in high-risk GIST (PERSIST-5): a randomised, multicentre, open-label, phase 3 trial’, The Lancet Oncology, 24(1), pp. 67–77. doi: 10.1016/S1470-2045(22)00682-8.
13. Schöffski, P. et al. (2022) ‘Regorafenib for the treatment of gastrointestinal stromal tumours’, Expert Opinion on Pharmacotherapy, 23(5), pp. 557–568. doi: 10.1080/14656566.2022.2040123.
14. Ströbel, P. et al. (2019) ‘Pediatric and young adult GIST: unique biology and therapeutic challenges’, Cancers, 11(11), p. 1724. doi: 10.3390/cancers11111724.
15. Van der Zwan, S.M. et al. (2018) ‘Incidence and survival of gastrointestinal stromal tumours in the Netherlands: a population-based study’, European Journal of Cancer, 92, pp. 87–95. doi: 10.1016/j.ejca.2018.01.015.
16. Yamaguchi, U. et al. (2020) ‘Molecular diagnosis and targeted therapy for gastrointestinal stromal tumors’, Cancers, 12(6), p. 1487. doi: 10.3390/cancers12061487.